
-
Adicet Bio NasdaqGM:ACET Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Location: 131 Dartmouth Street, Boston, MA, 02116, United States | Website: https://www.adicetbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-69.91M
Cash
150.4M
Avg Qtr Burn
-23.73M
Short % of Float
3.33%
Insider Ownership
2.77%
Institutional Own.
67.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Lupus nephritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1 Data readout | |
ADI-270 Details Cancer, Renal cell carcinoma | Phase 1 Data readout | |
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Data readout | |
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Idiopathic inflammatory myopathy / myositis, Stiff Person Syndrome | Phase 1 Initiation |